Derma Sciences Inc. (DSCI) Lifted to Buy at Zacks Investment Research
Derma Sciences Inc. (NASDAQ:DSCI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday. The firm presently has a $5.25 price objective on the stock. Zacks Investment Research’s price objective would suggest a potential upside of 12.90% from the stock’s current price.
According to Zacks, “Derma Sciences, Inc. is engaged in the development, marketing and sales of proprietary and non-proprietary topical, nutrient-based wound care products for the management of certain chronic, non-healing skin ulcerations such as pressure and venous ulcers, surgical incisions and burns. (PRESS RELEASE) “
Separately, TheStreet upgraded shares of Derma Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, August 9th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $7.25.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/derma-sciences-inc-dsci-lifted-to-buy-at-zacks-investment-research.html
Derma Sciences (NASDAQ:DSCI) traded up 1.09% during mid-day trading on Tuesday, reaching $4.65. 32,599 shares of the company traded hands. The stock’s 50 day moving average price is $4.68 and its 200 day moving average price is $4.24. The firm’s market capitalization is $131.62 million. Derma Sciences has a 52 week low of $2.85 and a 52 week high of $5.99.
Derma Sciences (NASDAQ:DSCI) last posted its quarterly earnings results on Tuesday, August 9th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.16. Derma Sciences had a negative net margin of 21.19% and a negative return on equity of 11.74%. The company earned $22.20 million during the quarter, compared to analysts’ expectations of $22.40 million. Equities analysts forecast that Derma Sciences will post ($0.04) EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in DSCI. BlackRock Institutional Trust Company N.A. increased its stake in Derma Sciences by 2.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 153,052 shares of the company’s stock valued at $603,000 after buying an additional 3,613 shares during the period. Dimensional Fund Advisors LP increased its stake in Derma Sciences by 15.6% in the second quarter. Dimensional Fund Advisors LP now owns 52,535 shares of the company’s stock valued at $207,000 after buying an additional 7,086 shares during the period. Vanguard Group Inc. increased its stake in Derma Sciences by 1.1% in the second quarter. Vanguard Group Inc. now owns 802,878 shares of the company’s stock valued at $3,163,000 after buying an additional 8,376 shares during the period. Granahan Investment Management Inc. MA increased its stake in Derma Sciences by 5.1% in the first quarter. Granahan Investment Management Inc. MA now owns 1,028,460 shares of the company’s stock valued at $3,188,000 after buying an additional 50,142 shares during the period. Finally, Emerald Acquisition Ltd. acquired a new stake in Derma Sciences during the second quarter valued at approximately $202,000. Hedge funds and other institutional investors own 62.44% of the company’s stock.
Derma Sciences Company Profile
Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Derma Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.